Open Access
- 20 September 2022
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Abstract
Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, and Alzheimer’s disease. Blocking FSH action prevents bone loss, fat gain, and neurodegeneration in mice. We recently developed a first-in-class, humanized, epitope-specific FSH-blocking antibody, MS-Hu6, with a KD of 7.52 nM. Using a Good Laboratory Practice (GLP)-compliant platform, we now report the efficacy of MS-Hu6 in preventing and treating osteoporosis in mice and parameters of acute safety in monkeys. Biodistribution studies using 89Zr-labeled, biotinylated or unconjugated MS-Hu6 in mice and monkeys showed localization to bone and bone marrow. The MS-Hu6 displayed a β phase t½ of 7.5 days (180 hr) in humanized Tg32 mice. We tested 217 variations of excipients using the protein thermal shift assay to generate a final formulation that rendered MS-Hu6 stable in solution upon freeze-thaw and at different temperatures, with minimal aggregation, and without self-, cross-, or hydrophobic interactions or appreciable binding to relevant human antigens. The MS-Hu6 showed the same level of “humanness” as human IgG1 in silico and was non-immunogenic in ELISpot assays for IL-2 and IFN-γ in human peripheral blood mononuclear cell cultures. We conclude that MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for future human testing.Keywords
All Related Versions
Funding Information
- National Institute on Aging (R01 AG071870)
- National Institute on Aging (R01 AG074092)
- National Institute on Aging (U01 AG073148)
- National Institute on Aging (U19 AG060917)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK113627)
- National Institute of General Medical Sciences (P20 GM121301)
This publication has 58 references indexed in Scilit:
- Developments and Challenges for mAb-Based TherapeuticsAntibodies, 2013
- Immunization with FSHβ fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis modelBiochemical and Biophysical Research Communications, 2013
- Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesisProceedings of the National Academy of Sciences, 2012
- Change in Follicle-Stimulating Hormone and Estradiol Across the Menopausal Transition: Effect of Age at the Final Menstrual PeriodThe Journal of Clinical Endocrinology & Metabolism, 2011
- Effects of Suppression of Follicle-Stimulating Hormone Secretion on Bone Resorption Markers in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Effects of the menopause transition and hormone use on cognitive performance in midlife womenNeurology, 2009
- Oxytocin is an anabolic bone hormoneProceedings of the National Academy of Sciences, 2009
- Changes in Body Composition in Women over Six Years at Midlife: Ovarian and Chronological AgingThe Journal of Clinical Endocrinology & Metabolism, 2007
- Why Most Published Research Findings Are FalsePLOS Medicine, 2005
- Elevated Gonadotropin Levels in Patients With Alzheimer DiseaseMayo Clinic Proceedings, 2001